Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 24 March 2014 | By Alexander Gaffney, RAC,
The European Commission's Scientific Committee on Emerging Newly Identified Health Risks (SCENIHR) -a scientific committee which conducts risk assessments for EU officials-has announced it is launching an investigation into the safety of transvaginal mesh products used in urogynecologic surgery.
Transvaginal mesh has been used to treat female urological conditions, and in particular those caused by weakened pelvic muscles, which can lead to a pelvic organ prolapse. In the EU, they have been used since the 1950s to repair abdominal hernias, and since the 1990s to treat stress urinary incontinence (SUI).
The products have been subject to numerous safety concerns, especially in the US, where the US Food and Drug Administration (FDA) has noted its "serious concern" about the safety of the devices.
A 2011 safety communication by FDA identified thousands of adverse events associated with the devices, including mesh erosion, pain, infection, bleeding, dyspareunia, organ perforation and urinary problems. FDA has also required the companies to study rates of organ damage and conduct at least three years of safety studies, according to Bloomberg.
FDA did not remove the products from the market, but one major manufacturer, Johnson & Johnson, announced it would cease marketing the product in June 2012.
Numerous other companies still market the device in both the US and EU.
But in the EU, where medical devices are regulated on a country-by-country level, and not by the European Medicines Agency (EMA), regulators have been slower to ramp up their scrutiny of the device.
That's now changing.
On 21 March 2014, SCENIHR announced that the European Commission had requested that it deliver an opinion regarding the safety of transvaginal mesh devices used in urogynecologic surgery.
"Current data suggest that the use of mesh in surgery is associated with both benefits and risks, but few randomized controlled trials have been published," the commission wrote in its request to SCENIHR. The EC also noted many of the same adverse events highlighted by FDA, and said that it wants to know more about the factors that result in increased risks for consumers.
In particular, SCENIHR is directed to determine:
The committee is now calling for experts to help it conduct a "comprehensive assessment" of the safety of the devices, and hopes to receive responses by April 2014.
SCENIHR Notice
Tags: SCENIHR, Transvaginal Mesh, European Commission, Latest News, safety, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.